Tryptamine Therapeutics (ASX:TYP) entered into a loan facility agreement with funding firm, Rockford Equity, for the company's AU$2.6 million research and development activities, according to a Tuesday filing with the Australian bourse.
The company can borrow in AU$500,000 amounts from the facility, with interest of 16% per year on the outstanding balance, the filing said.
Shares of the company rose past 3% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.